Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1990 May;4(3):276-83.
doi: 10.1007/BF00857676.

Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes

Affiliations
Review

Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes

B S Kaplan et al. Pediatr Nephrol. 1990 May.

Abstract

One of the requirements for an agent to cause hemolytic uremic syndrome (HUS) is its ability to injure endothelial cells. Shiga-like toxin (SLT) can do this. SLT is produced by Escherichia coli and Shigella dysenteriae serotype 1; both have been implicated as causes of typical HUS. Endothelial cells have receptors (GB3) for SLT and the toxin can inhibit eukaryotic protein synthesis, thereby causing cell death. Glomerular endothelial cell injury or death results in a decreased glomerular filtration rate and many of the perturbations seen in HUS. It is no longer certain that hemolysis is the result of a microangiopathy. Cell injury results in release of von Willebrand multimers; if these are ultra-large, thrombosis may ensue. There is also increasing evidence that neutrophils have a role in the pathogenesis of typical HUS. Streptococcus pneumoniae can also cause HUS and care must be taken to avoid giving plasma to patients with S. pneumoniae-associated HUS. There is compelling evidence that types of HUS are inherited by autosomal recessive and autosomal dominant modes. Patients with autosomal recessive HUS may have recurrent episodes. Mortality and morbidity rates are high for the inherited forms.

PubMed Disclaimer

Comment in

  • Paucisymptomatic hemolytic uremic syndrome.
    von Vigier RO, Offermann N, Beretta-Piccoli BC, Bianchetti MG. von Vigier RO, et al. Pediatr Nephrol. 2000 May;14(5):436-7. Pediatr Nephrol. 2000. PMID: 10805475 No abstract available.

References

    1. J Clin Invest. 1986 Apr;77(4):1233-43 - PubMed
    1. Semin Hematol. 1987 Jul;24(3):161-77 - PubMed
    1. Haemostasis. 1984;14(5):373-7 - PubMed
    1. Infect Immun. 1982 Jun;36(3):996-1005 - PubMed
    1. Blood. 1988 Aug;72(2):721-7 - PubMed

LinkOut - more resources